Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice

被引:56
作者
Hong, Seong Keun [1 ]
Kim, Hee Joo [1 ]
Song, Chang Seon [1 ]
Choi, In Soo [1 ]
Lee, Joong Bok [1 ]
Park, Seung Yong [1 ]
机构
[1] Konkuk Univ, Coll Vet Med, Dept Immunol, Seoul 143701, South Korea
关键词
Nitazoxanide; Interleukin-6; Thioglycollate; RAW; 264.7; cells; Lipopolysaccharide; ANTIPARASITIC DRUG NITAZOXANIDE; HELICOBACTER-PYLORI; IN-VITRO; INTERLEUKIN-6; CYTOKINE; INFLAMMATION; INHIBITION; ACTIVATION; FAMILY; SERUM;
D O I
10.1016/j.intimp.2012.03.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Suppression of interleukin (IL)-6 production has beneficial effects against various inflammatory diseases. Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 cells and mouse peritoneal macrophages, with 50% inhibitory concentrations (IC50S) of 1.54 mM and 0.17 mM, respectively. Nitazoxanide also inhibited the LPS-induced expression of IL-6 mRNA in RAW 264.7 cells. To investigate the effects of nitazoxanide in vivo, we orally administered nitazoxanide at a dose of 100 mg/kg to mice 2 h before a 1-mL intraperitoneal injection of 4% thioglycollate (TG). Six hours after TG injection, plasma IL-6 levels were markedly lower (by 90%) than the levels in vehicle-treated mice. These data suggest that nitazoxanide could be a promising lead compound for agents against various diseases associated with overproduction of IL-6. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 29 条
[1]
Distinct pathways of LPS-induced NF-κB activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP [J].
Andreakos, E ;
Sacre, SM ;
Smith, C ;
Lundberg, A ;
Kiriakidis, S ;
Stonehouse, T ;
Monaco, C ;
Feldmann, M ;
Foxwell, BM .
BLOOD, 2004, 103 (06) :2229-2237
[2]
Ashton LV, 2010, VET MED INT, V2010
[3]
Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1 [J].
Benigni, F ;
Fantuzzi, G ;
Sacco, S ;
Sironi, M ;
Pozzi, P ;
Dinarello, CA ;
Sipe, JD ;
Poli, V ;
Cappelletti, M ;
Paonessa, G ;
Pennica, D ;
Panayotatos, N ;
Ghezzi, P .
BLOOD, 1996, 87 (05) :1851-1854
[4]
Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond [J].
Bobak D.A. .
Current Infectious Disease Reports, 2006, 8 (2) :91-95
[5]
In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms [J].
Dubreuil, L ;
Houcke, I ;
Mouton, Y ;
Rossignol, JF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2266-2270
[6]
FATTORI E, 1994, BLOOD, V83, P2570
[7]
Nematocidal activity of nitazoxanide in laboratory models [J].
Fonseca-Salamanca, F ;
Martínez-Grueiro, MM ;
Martínez-Fernández, AR .
PARASITOLOGY RESEARCH, 2003, 91 (04) :321-324
[8]
Drug treatment and novel drug target against Cryptosporidium [J].
Gargala, G. .
PARASITE, 2008, 15 (03) :275-281
[9]
INTERLEUKIN-6 PRODUCTION IN THE CENTRAL-NERVOUS-SYSTEM DURING EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS [J].
GIJBELS, K ;
VANDAMME, J ;
PROOST, P ;
PUT, W ;
CARTON, H ;
BILLIAU, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (01) :233-235
[10]
Nitazoxanide in treatment of Helicobacter pylori:: a clinical and in vitro study [J].
Guttner, Y ;
Windsor, HM ;
Viiala, CH ;
Dusci, L ;
Marshall, BJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3780-3783